Estrella Immunopharma (ESLA) Competitors $2.38 +0.05 (+2.15%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$2.37 -0.01 (-0.63%) As of 10/24/2025 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ESLA vs. CRBU, VOR, TRDA, EPRX, BDTX, PYXS, GNFT, ACRS, TARA, and BHSTShould you be buying Estrella Immunopharma stock or one of its competitors? The main competitors of Estrella Immunopharma include Caribou Biosciences (CRBU), Vor Biopharma (VOR), Entrada Therapeutics (TRDA), Eupraxia Pharmaceuticals (EPRX), Black Diamond Therapeutics (BDTX), Pyxis Oncology (PYXS), GENFIT (GNFT), Aclaris Therapeutics (ACRS), Protara Therapeutics (TARA), and BioHarvest Sciences (BHST). These companies are all part of the "pharmaceutical products" industry. Estrella Immunopharma vs. Its Competitors Caribou Biosciences Vor Biopharma Entrada Therapeutics Eupraxia Pharmaceuticals Black Diamond Therapeutics Pyxis Oncology GENFIT Aclaris Therapeutics Protara Therapeutics BioHarvest Sciences Caribou Biosciences (NASDAQ:CRBU) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk. Is CRBU or ESLA more profitable? Estrella Immunopharma has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,800.93%. Caribou Biosciences' return on equity of -62.35% beat Estrella Immunopharma's return on equity.Company Net Margins Return on Equity Return on Assets Caribou Biosciences-1,800.93% -62.35% -49.65% Estrella Immunopharma N/A -1,132.38%-358.54% Do analysts rate CRBU or ESLA? Caribou Biosciences currently has a consensus target price of $6.67, suggesting a potential upside of 167.74%. Estrella Immunopharma has a consensus target price of $16.00, suggesting a potential upside of 572.27%. Given Estrella Immunopharma's higher possible upside, analysts plainly believe Estrella Immunopharma is more favorable than Caribou Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Caribou Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50Estrella Immunopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has more volatility and risk, CRBU or ESLA? Caribou Biosciences has a beta of 2.59, meaning that its stock price is 159% more volatile than the S&P 500. Comparatively, Estrella Immunopharma has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500. Does the media prefer CRBU or ESLA? In the previous week, Caribou Biosciences and Caribou Biosciences both had 2 articles in the media. Estrella Immunopharma's average media sentiment score of 1.91 beat Caribou Biosciences' score of 1.06 indicating that Estrella Immunopharma is being referred to more favorably in the news media. Company Overall Sentiment Caribou Biosciences Positive Estrella Immunopharma Very Positive Which has stronger earnings and valuation, CRBU or ESLA? Estrella Immunopharma has lower revenue, but higher earnings than Caribou Biosciences. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCaribou Biosciences$9.99M23.21-$149.10M-$1.78-1.40Estrella ImmunopharmaN/AN/AN/A-$0.30-7.93 Do institutionals & insiders believe in CRBU or ESLA? 77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 0.3% of Estrella Immunopharma shares are held by institutional investors. 8.3% of Caribou Biosciences shares are held by company insiders. Comparatively, 55.1% of Estrella Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryCaribou Biosciences beats Estrella Immunopharma on 8 of the 13 factors compared between the two stocks. Get Estrella Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ESLA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ESLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESLA vs. The Competition Export to ExcelMetricEstrella ImmunopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$86.36M$3.43B$6.24B$10.67BDividend YieldN/A2.27%5.72%4.81%P/E Ratio-7.9326.8131.1930.71Price / SalesN/A451.95560.36173.93Price / CashN/A46.1437.0861.44Price / BookN/A10.4012.056.61Net IncomeN/A-$52.83M$3.33B$277.10M7 Day Performance36.00%2.10%1.93%2.56%1 Month Performance103.42%12.33%7.77%3.77%1 Year Performance164.44%14.14%56.40%33.01% Estrella Immunopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESLAEstrella Immunopharma3.0221 of 5 stars$2.38+2.1%$16.00+572.3%+179.7%$86.36MN/A-7.93N/ANews CoveragePositive NewsShort Interest ↓High Trading VolumeCRBUCaribou Biosciences2.8315 of 5 stars$2.44+2.5%$6.67+173.2%+36.8%$221.63M$9.12M-1.37100News CoveragePositive NewsAnalyst ForecastGap UpVORVor Biopharma2.5794 of 5 stars$30.81-4.6%$113.83+269.5%N/A$221.31MN/A-0.11140Analyst ForecastInsider TradeTRDAEntrada Therapeutics3.297 of 5 stars$6.06+4.3%$25.67+323.5%-59.4%$221.00M$79.48M-3.40110News CoverageAnalyst ForecastEPRXEupraxia Pharmaceuticals3.0054 of 5 stars$5.87-3.0%$11.00+87.4%+119.7%$217.56MN/A-6.9129Analyst ForecastShort Interest ↑BDTXBlack Diamond Therapeutics3.9722 of 5 stars$3.76-1.1%$11.00+192.6%+29.3%$216.35MN/A16.3590Positive NewsAnalyst ForecastPYXSPyxis Oncology2.9742 of 5 stars$3.23-6.4%$7.75+139.9%-7.7%$213.96M$2.82M-2.0260Analyst ForecastGNFTGENFIT2.1506 of 5 stars$4.10-3.5%$7.00+70.7%-23.3%$212.51M$76.77M0.00120ACRSAclaris Therapeutics2.5121 of 5 stars$1.81-5.2%$8.71+381.5%+66.7%$206.91M$18.72M-1.32100Positive NewsGap UpTARAProtara Therapeutics1.8534 of 5 stars$5.36+0.4%$19.60+265.7%+155.0%$206.03MN/A-3.3130News CoverageAnalyst ForecastBHSTBioHarvest Sciences2.2805 of 5 stars$12.03-3.8%$13.67+13.6%N/A$205.31M$30.19M-17.19N/ANews CoverageAnalyst ForecastShort Interest ↑ Related Companies and Tools Related Companies Caribou Biosciences Competitors Vor Biopharma Competitors Entrada Therapeutics Competitors Eupraxia Pharmaceuticals Competitors Black Diamond Therapeutics Competitors Pyxis Oncology Competitors GENFIT Competitors Aclaris Therapeutics Competitors Protara Therapeutics Competitors BioHarvest Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ESLA) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Estrella Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Estrella Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ESLA Stock Alerts